Lance Alstodt - Dec 7, 2022 Form 4 Insider Report for BioRestorative Therapies, Inc. (BRTX)

Role
President, CEO, COB, Director
Signature
/s/ Lance Alstodt
Stock symbol
BRTX
Transactions as of
Dec 7, 2022
Transactions value $
$5,375
Form type
4
Date filed
12/7/2022, 05:04 PM
Previous filing
Nov 21, 2022
Next filing
Dec 28, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction BRTX Common Stock Purchase $5.37K +1.8K +0.98% $2.99 186K Dec 7, 2022 Direct F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding BRTX Stock Option 293K Dec 7, 2022 Common Stock 293K $5.08 Direct F3
holding BRTX Stock Option 42.1K Dec 7, 2022 Common Stock 42.1K $5.08 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This transaction was executed in multiple trades at prices ranging from $2.93 to $3.00 per share. The price reported above reflects the weighted average purchase price. The reporting person hereby undertakes to provide, upon request to the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares and prices at which the transactions were effected.
F2 Includes 101,972 shares received pursuant to an unvested restricted stock unit grant. Such shares vest to the extent of 1,037 shares on December 18, 2022 and February 18, 2023, 1,036 shares on January 18, 2023, 49,949 shares on March 18, 2023 and 48,913 shares on March 18, 2024.
F3 The option vests and becomes exercisable to the extent of 146,740 shares on March 18, 2021, 36,684 shares on November 4, 2021 with the remaining 110,055 shares in six nearly equal quarterly installments beginning December 18, 2021 and continuing every three months thereafter until fully vested.
F4 The option vests and becomes exercisable to the extent of 21,030 shares on November 4, 2021 with the remaining 21,029 shares vesting quarterly in eight nearly equal installments beginning on November 4, 2022.